156 related articles for article (PubMed ID: 647634)
21. MVP immunohistochemistry is a useful adjunct in distinguishing leiomyosarcoma from leiomyoma and leiomyoma with bizarre nuclei.
Lintel NJ; Luebker SA; Lele SM; Koepsell SA
Hum Pathol; 2018 Mar; 73():122-127. PubMed ID: 29307622
[TBL] [Abstract][Full Text] [Related]
22. Hemorrhagic cellular leiomyomas ("apoplectic leiomyoma") of the uterus associated with pregnancy and oral contraceptives.
Norris HJ; Hilliard GD; Irey NS
Int J Gynecol Pathol; 1988; 7(3):212-24. PubMed ID: 3182168
[TBL] [Abstract][Full Text] [Related]
23. Uterine leiomyosarcoma - incidence, treatment, and the impact of morcellation. A nationwide cohort study.
Skorstad M; Kent A; Lieng M
Acta Obstet Gynecol Scand; 2016 Sep; 95(9):984-90. PubMed ID: 27223683
[TBL] [Abstract][Full Text] [Related]
24. Uterine leiomyomas with bizarre nuclei: a clinicopathologic study of 59 cases.
Croce S; Young RH; Oliva E
Am J Surg Pathol; 2014 Oct; 38(10):1330-9. PubMed ID: 25140893
[TBL] [Abstract][Full Text] [Related]
25. Mitotically active leiomyomas of the uterus.
Prayson RA; Hart WR
Am J Clin Pathol; 1992 Jan; 97(1):14-20. PubMed ID: 1728856
[TBL] [Abstract][Full Text] [Related]
26. Potential diagnostic biomarkers: differential expression of LMP2/β1i and cyclin B1 in human uterine leiomyosarcoma.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Ichimura T; Sudo T; Ishiko O; Yaegashi N; Aburatani H; Konishi I
Tumori; 2014; 100(4):99e-106e. PubMed ID: 25296613
[TBL] [Abstract][Full Text] [Related]
27. Leiomyoma and Leiomyosarcoma (Primary and Metastatic) of the Oral and Maxillofacial Region: A Clinicopathological and Immunohistochemical Study of 27 Cases.
de Araújo GR; Costa SFDS; Mesquita RA; Gomez RS; Dos Santos JN; Pontes HAR; de Andrade BAB; Romañach MJ; Agostini M; Vargas PA; de Cáceres CVBL; Santos-Silva AR; Ribeiro ACP; Brandão TB; Tomasi RA; Ferreyra RS; de Almeida OP; Fonseca FP
Head Neck Pathol; 2022 Mar; 16(1):294-303. PubMed ID: 34106410
[TBL] [Abstract][Full Text] [Related]
28. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior.
Giuntoli RL; Gostout BS; DiMarco CS; Metzinger DS; Keeney GL
J Reprod Med; 2007 Nov; 52(11):1001-10. PubMed ID: 18161397
[TBL] [Abstract][Full Text] [Related]
30. [Differential diagnosis of cellular leiomyomas and leiomyoplastic sarcomas].
Cupr Z; Rohanova M; Holle V; Sikula M
Zentralbl Gynakol; 1972 Jan; 94(3):101-8. PubMed ID: 5017233
[No Abstract] [Full Text] [Related]
31. Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study.
Raspagliesi F; Maltese G; Bogani G; Fucà G; Lepori S; De Iaco P; Perrone M; Scambia G; Cormio G; Bogliolo S; Bergamini A; Bifulco G; Casali PG; Lorusso D
Gynecol Oncol; 2017 Jan; 144(1):90-95. PubMed ID: 27817933
[TBL] [Abstract][Full Text] [Related]
32. [Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].
Horn LC; Hiller GGR; Mayr D; Schmoeckel E; Höhn AK
Pathologe; 2022 May; 43(3):196-201. PubMed ID: 35412039
[TBL] [Abstract][Full Text] [Related]
33. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
[TBL] [Abstract][Full Text] [Related]
34. A scoring system for histopathologic and immunohistochemical evaluations of uterine leiomyosarcomas.
Yoshida C; Ichimura T; Kawamura N; Nakano A; Kasai M; Sumi T; Ishiko O
Oncol Rep; 2009 Oct; 22(4):725-31. PubMed ID: 19724849
[TBL] [Abstract][Full Text] [Related]
35. Prognostically favorable "mitotically active" smooth-muscle tumors of the uterus. A clinicopathologic study of ten cases.
Perrone T; Dehner LP
Am J Surg Pathol; 1988 Jan; 12(1):1-8. PubMed ID: 3337336
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic study of 28 uterine leiomyosarcomas with metastasis.
Jones MW; Norris HJ
Int J Gynecol Pathol; 1995 Jul; 14(3):243-9. PubMed ID: 8600076
[TBL] [Abstract][Full Text] [Related]
37. Mesenchymal tumors of the uterus. VI. Epithelioid smooth muscle tumors including leiomyoblastoma and clear-cell leiomyoma: a clinical and pathologic analysis of 26 cases.
Kurman RJ; Norris HJ
Cancer; 1976 Apr; 37(4):1853-65. PubMed ID: 56982
[TBL] [Abstract][Full Text] [Related]
38. Identification of uterine leiomyoma-specific marker genes based on DNA methylation and their clinical application.
Sato S; Maekawa R; Yamagata Y; Tamura I; Lee L; Okada M; Jozaki K; Asada H; Tamura H; Sugino N
Sci Rep; 2016 Aug; 6():30652. PubMed ID: 27498619
[TBL] [Abstract][Full Text] [Related]
39. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum: a pathologic analysis of 100 cases.
Ranchod M; Kempson RL
Cancer; 1977 Jan; 39(1):255-62. PubMed ID: 832238
[TBL] [Abstract][Full Text] [Related]
40. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
